Eli Lilly’s lone grant of experimental obesity drug sparks clinician frustration

The pharmaceutical firm provided a single senior patient with the unapproved drug retatrutide, which has shown weight-loss results comparable to bariatric surgery. Since the case was reported, several physicians have reached out to Lilly seeking the same treatment for their patients, but many have received no response. One doctor only learned his patient might qualify after the media contacted the company. The silence has prompted calls for clearer guidance on whether the access was an isolated exception or part of a broader plan.